PT2951208T - Anticorpos anti-cd83 e sua utilização - Google Patents
Anticorpos anti-cd83 e sua utilizaçãoInfo
- Publication number
- PT2951208T PT2951208T PT147456370T PT14745637T PT2951208T PT 2951208 T PT2951208 T PT 2951208T PT 147456370 T PT147456370 T PT 147456370T PT 14745637 T PT14745637 T PT 14745637T PT 2951208 T PT2951208 T PT 2951208T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759780P | 2013-02-01 | 2013-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2951208T true PT2951208T (pt) | 2019-12-30 |
Family
ID=51261317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147456370T PT2951208T (pt) | 2013-02-01 | 2014-01-31 | Anticorpos anti-cd83 e sua utilização |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9840559B2 (pt) |
| EP (2) | EP3626743A1 (pt) |
| JP (2) | JP6539585B2 (pt) |
| KR (2) | KR102204127B1 (pt) |
| CN (1) | CN105531289B (pt) |
| AU (1) | AU2014213009B2 (pt) |
| CA (1) | CA2899960C (pt) |
| DK (1) | DK2951208T3 (pt) |
| ES (1) | ES2762622T3 (pt) |
| MX (1) | MX2015010023A (pt) |
| NZ (1) | NZ711543A (pt) |
| PT (1) | PT2951208T (pt) |
| WO (1) | WO2014117220A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ711543A (en) | 2013-02-01 | 2020-08-28 | Univ California | Anti-cd83 antibodies and use thereof |
| CA2965170A1 (en) * | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
| EP3681536A4 (en) * | 2017-09-13 | 2021-06-09 | Kira Biotech Pty Limited | TREATMENT PROCEDURES |
| SG11202007755YA (en) * | 2018-02-23 | 2020-09-29 | H Lee Moffitt Cancer Ct & Res | Cd83-binding chimeric antigen receptors |
| EP4004051A4 (en) | 2019-07-19 | 2023-08-23 | Oncoresponse, Inc. | IMMUNOMODULATING ANTIBODIES AND METHODS OF USE THEREOF |
| CN114615992A (zh) * | 2019-08-16 | 2022-06-10 | H.李.莫菲特癌症中心和研究所股份有限公司 | 表达t调节性细胞的抗cd83嵌合抗原受体 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0302894B1 (en) | 1986-04-28 | 1992-11-19 | Endotronics Inc. | Method of culturing leukocytes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| DE4211351A1 (de) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
| AU3691093A (en) | 1992-04-14 | 1993-10-21 | Hybritech Incorporated | Methods of inhibiting the growth of multidrug resistant tumors |
| US5316920A (en) | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
| US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
| WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6562622B1 (en) | 1998-05-08 | 2003-05-13 | Diatech Pty, Ltd | Continuous in vitro evolution |
| ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6566051B1 (en) | 1999-01-15 | 2003-05-20 | Medtox Scientific, Inc. | Lateral flow test strip |
| JP2002541195A (ja) * | 1999-04-14 | 2002-12-03 | アメリカ合衆国 | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 |
| US7270969B2 (en) | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| JP4264348B2 (ja) | 2001-08-20 | 2009-05-13 | プロテオム システムズ リミテッド | 診断検査方法および装置 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| AU2002357759A1 (en) | 2001-11-21 | 2003-06-10 | Mark W. Appelby | Manipulation of cytokine levels using cd83 gene products |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003302132B2 (en) | 2002-11-21 | 2008-02-21 | Inverness Medical Switzerland Gmbh | Bodily fluid markers of tissue hypoxia |
| EP2258724A1 (en) | 2002-11-21 | 2010-12-08 | Celltech R & D, Inc. | Modulating immune responses using multimerized anti-CD83 antibodies |
| US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20070292416A1 (en) | 2003-06-02 | 2007-12-20 | Alexion Pharmaceuticals, Inc. | De-Immunized Anti-Cd3 Antibody |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1819731A4 (en) * | 2004-12-08 | 2013-02-13 | Immunomedics Inc | METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER |
| EP1872125A4 (en) | 2005-03-31 | 2009-04-01 | Telethon Inst For Child Health | ISOLATION OF INHIBITOR OF IRES-MEDIATED TRANSLATION |
| KR20150032915A (ko) * | 2005-04-08 | 2015-03-30 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
| CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| EP2041175A4 (en) * | 2006-06-23 | 2011-03-16 | Augmenta Biolog Llc | TARGETED IMMUNOJUGATE |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2009157623A1 (en) * | 2008-06-25 | 2009-12-30 | Korea Research Institute Of Bioscience And Biotechnology | Cd9-specific human antibodies |
| AR074369A1 (es) | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
| WO2012088290A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| NZ711543A (en) | 2013-02-01 | 2020-08-28 | Univ California | Anti-cd83 antibodies and use thereof |
| CA2965170A1 (en) | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
| EP3681536A4 (en) | 2017-09-13 | 2021-06-09 | Kira Biotech Pty Limited | TREATMENT PROCEDURES |
-
2014
- 2014-01-31 NZ NZ711543A patent/NZ711543A/en not_active IP Right Cessation
- 2014-01-31 AU AU2014213009A patent/AU2014213009B2/en active Active
- 2014-01-31 CA CA2899960A patent/CA2899960C/en active Active
- 2014-01-31 DK DK14745637.0T patent/DK2951208T3/da active
- 2014-01-31 MX MX2015010023A patent/MX2015010023A/es active IP Right Grant
- 2014-01-31 KR KR1020157023660A patent/KR102204127B1/ko active IP Right Grant
- 2014-01-31 KR KR1020207029681A patent/KR102449868B1/ko active IP Right Grant
- 2014-01-31 CN CN201480011458.5A patent/CN105531289B/zh active Active
- 2014-01-31 US US14/765,236 patent/US9840559B2/en active Active
- 2014-01-31 EP EP19203675.4A patent/EP3626743A1/en not_active Withdrawn
- 2014-01-31 JP JP2015555498A patent/JP6539585B2/ja active Active
- 2014-01-31 ES ES14745637T patent/ES2762622T3/es active Active
- 2014-01-31 PT PT147456370T patent/PT2951208T/pt unknown
- 2014-01-31 EP EP14745637.0A patent/EP2951208B1/en active Active
- 2014-01-31 WO PCT/AU2014/000066 patent/WO2014117220A1/en active Application Filing
-
2017
- 2017-11-09 US US15/808,423 patent/US10781255B2/en active Active
-
2019
- 2019-01-04 JP JP2019000340A patent/JP2019076102A/ja active Pending
-
2020
- 2020-07-09 US US16/924,860 patent/US11725054B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102204127B1 (ko) | 2021-01-20 |
| EP2951208A1 (en) | 2015-12-09 |
| US11725054B2 (en) | 2023-08-15 |
| US10781255B2 (en) | 2020-09-22 |
| KR20200120967A (ko) | 2020-10-22 |
| EP2951208A4 (en) | 2016-10-19 |
| US9840559B2 (en) | 2017-12-12 |
| KR102449868B1 (ko) | 2022-10-04 |
| JP6539585B2 (ja) | 2019-07-03 |
| WO2014117220A1 (en) | 2014-08-07 |
| NZ711543A (en) | 2020-08-28 |
| CA2899960C (en) | 2022-05-03 |
| JP2019076102A (ja) | 2019-05-23 |
| DK2951208T3 (da) | 2020-01-13 |
| JP2016507521A (ja) | 2016-03-10 |
| EP3626743A1 (en) | 2020-03-25 |
| EP2951208B1 (en) | 2019-11-13 |
| US20180201681A1 (en) | 2018-07-19 |
| KR20150135250A (ko) | 2015-12-02 |
| CA2899960A1 (en) | 2014-08-07 |
| AU2014213009A1 (en) | 2015-09-17 |
| US20150376277A1 (en) | 2015-12-31 |
| AU2014213009B2 (en) | 2019-01-03 |
| US20200339684A1 (en) | 2020-10-29 |
| ES2762622T3 (es) | 2020-05-25 |
| CN105531289B (zh) | 2019-02-22 |
| MX2015010023A (es) | 2017-11-17 |
| CN105531289A (zh) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261743B (en) | and their uses 33–il antibodies against | |
| HK1232243A1 (zh) | 抗- 抗體及其用途 | |
| IL261547B (en) | Antibodies against pesidine and their uses | |
| IL245040A0 (en) | Antibodies against pdgfr-beta and their uses | |
| IL243974A0 (en) | Antibodies against -prlr and uses | |
| ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
| HK1223544A1 (zh) | 抗體製劑和方法 | |
| PT3026062T (pt) | Anticorpo anti-pd-1 e utilização do mesmo | |
| HUE051982T2 (hu) | Anti-alfa-szinuklein antitestek és alkalmazási eljárások | |
| SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof | |
| HK1225612A1 (zh) | 抗ly6e抗體及使用方法 | |
| GB201305277D0 (en) | Novel combination and use | |
| EP2951208A4 (en) | ANTI-CD83 ANTIBODIES AND THEIR USE | |
| GB201307989D0 (en) | Novel combinations and use | |
| ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
| GB201310502D0 (en) | Device and methods | |
| GB201301393D0 (en) | Kiddibidet and pottibidet | |
| GB201314232D0 (en) | Device and methods | |
| GB201301951D0 (en) | Device and methods |